Haemonetics Corporation
Price Action
Technical Summary
CONSOLIDATINGHaemonetics Corporation is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 42), showing significant lag compared to the market leaders. Earnings growth of 28% provides fundamental context to the price action. Investors should exercise caution due to high volatility (51% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $59.17 | -11.04% | BELOW |
| 50 SMA | $59.61 | -11.69% | BELOW |
| 100 SMA | $65.79 | -19.99% | BELOW |
| 150 SMA | $64.98 | -18.99% | BELOW |
| 200 SMA | $63.26 | -16.78% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is HAE in an uptrend right now?
HAE has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is HAE overbought or oversold?
HAE's RSI (14) is 38. The stock is in neutral territory, neither overbought nor oversold.
Is HAE outperforming the market?
HAE has a Relative Strength (RS) Rating of 42 out of 99. HAE is currently lagging the broader market.
Where is HAE in its 52-week range?
HAE is trading at $52.64, which is 60% of its 52-week high ($87.32) and 13% above its 52-week low ($47.32).
How volatile is HAE?
HAE has a Beta of 0.48 and 52-week volatility of 51%. It's less volatile than the S&P 500 - generally more stable.